Using smart nanoparticles to target specific RNA for treating aggressive breast cancer
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
This study is exploring a new way to treat triple-negative breast cancer by using tiny particles to deliver special treatments that can target and shut down harmful genes, which could help make existing therapies work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10991719 on NIH RePORTER |
What this research studies
This research focuses on developing innovative nanoparticles that can deliver targeted therapy to combat triple-negative breast cancer (TNBC). By specifically targeting oncogenic long non-coding RNAs (lncRNAs) that contribute to tumor growth and drug resistance, the study aims to improve treatment outcomes for patients with this aggressive cancer type. The approach involves using lipid nanoparticles to deliver small interfering RNA (siRNA) that can suppress the activity of these harmful lncRNAs, potentially reducing tumor proliferation and enhancing the effectiveness of existing therapies. Patients may benefit from a more effective treatment option that addresses the unique challenges posed by TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple-negative breast cancer who are facing challenges with current treatment options.
Not a fit: Patients with other subtypes of breast cancer or those who do not have breast cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with triple-negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise in using targeted RNA therapies for cancer treatment, indicating that this approach could lead to significant advancements in the field.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Lu, Zheng-Rong — Case Western Reserve University
- Study coordinator: Lu, Zheng-Rong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.